Your ability to conceive might remain unexplained when standard fertility testing produces normal results. Routine evaluations examine ovarian reserve, fallopian tube patency, and sperm characteristics, but other reproductive factors require separate assessment. For IVF patients or those pursuing IVF, additional testing provides information about the uterine environment. Here are testing options that may provide additional information when unexplained infertility remains under evaluation:
BCL6 Level Testing
BCL6 testing examines a protein marker found through an endometrial biopsy. Elevated BCL6 expression is associated with inflammation in the uterine lining and endometriosis. The result provides information about an area that routine fertility evaluations do not directly assess. For patients preparing for IVF, the finding may add another factor to the fertility evaluation.
Endometriosis may affect fertility even without typical symptoms. Some patients have no pelvic pain, painful periods, or painful intercourse, so symptom history alone does not provide all the relevant data. A biopsy provides tissue for laboratory analysis, while BCL6 testing examines a specific marker within that sample.
BCL6 testing also relates to situations involving implantation concerns and recurrent pregnancy loss. The result does not establish a complete treatment plan, as clinical findings must be interpreted in the context of the patient’s reproductive history. Instead, it provides another data point to discuss with a fertility specialist.
Endometrial Tissue Testing
Endometrial biopsy also provides a broader histological assessment of the uterine lining. Histology examines the collected tissue rather than focusing on a single biomarker. The analysis includes endometrial dating, cycle-phase confirmation, and abnormal cellular changes. Such findings provide additional information when routine fertility testing has not identified a specific cause.
Biopsy timing affects how the uterine lining is evaluated. Natural-cycle collection is performed seven to ten days after ovulation, while IVF mock-cycle testing follows progesterone exposure. Appropriate timing ensures the sample reflects the endometrium’s intended stage. An unexplained infertility provider coordinates collection based on the testing approach being used.
CD138 Testing
CD138 testing offers an additional analytical option when chronic endometritis is part of the clinical question. Chronic endometritis involves inflammation of the uterine lining and may be associated with reproductive problems. Plasma cells in endometrial tissue are associated with this condition.
Several details help explain how the additional analysis fits within fertility testing:
- CD138 identifies plasma cells within the endometrial tissue.
- The analysis relates to chronic endometritis.
- One biopsy sample may support both analyses.
- The finding gives providers another factor for clinical review.
- Results remain part of the broader fertility evaluation.
Patients pursuing IVF may discuss CD138 testing with their provider when chronic endometritis warrants investigation. Combining analyses from one sample provides information about different aspects of the uterine lining. Clinical interpretation remains dependent on the patient’s symptoms, reproductive history, and other test results.
Natural-Cycle Biopsy
One way of obtaining an endometrial sample is a natural-cycle biopsy. The procedure is timed to occur seven to ten days after ovulation, thereby collecting material at a specific point in the menstrual cycle. During an office visit, a thin catheter is inserted into the uterus to remove cells from the uterine lining. Selected laboratory analyses are performed on the sample.
Using a natural cycle, timing is incorporated into the testing process. Patients can discuss with their fertility provider when they should collect. The lab sends results back to the ordering provider for review. The provider will then use these results to explain them in the context of the patient’s fertility assessment.
Mock-Cycle Biopsy
IVF patients have another biopsy approach through testing during a mock cycle. The sample is collected after progesterone exposure, with the timing based on the protocol described for fertility testing. Collection occurs six to ten days after progesterone begins, with five full days of exposure before the biopsy. This approach provides an endometrial sample under conditions associated with an IVF treatment cycle. Key details distinguish mock-cycle collection from natural-cycle testing:
- Progesterone exposure: Collection follows progesterone administration during the mock cycle.
- Collection timing: Biopsy occurs six to ten days after progesterone begins.
- Exposure period: The protocol includes five full days of progesterone before collection.
- IVF context: The approach is designed for patients undergoing IVF preparation.
- Clinical review: The ordering provider receives the laboratory results for interpretation.
Learn More About Unexplained Infertility
Additional endometrial information may provide a different perspective when standard fertility evaluations leave questions unanswered. IVF or potential IVF patients may discuss which testing approach fits their reproductive history and treatment plans. A fertility specialist can explain the differences between natural-cycle and mock-cycle collection before testing begins. Discuss unexplained infertility testing options with your fertility provider to determine which evaluation fits your circumstances.
